Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming Billy Kelleher .
Filed returns
6
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs on pharmaceutical manufacturing and supply of medicines to patients globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | The Anti-Microbial Resistance Plan was due for publication in September 2017. The 3-year Plan covers the use of anti-microbial medicines in animal health and agriculture, and human health - taking a 'One Health'… (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2016 | Pfizer | Health | The Health (pricing and supply of medical goods) Act 2013 states that biologic medicines are out of scope for interchangeability. Biologic medicines are typically infusions and injections for diseases such as rheumatoid… (Legislation) | 5 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 3 | 50.0% | |
| EU Affairs | 2 | 33.3% | |
| Trade | 1 | 16.7% |